中文

Hong Kong Stocks · Free Data Page

JINHAI MED TECH 02225

JINHAI MED TECH: FY2025 revenue HK$46.3M (-7.90% YoY); net income -HK$17.1M; 3 alerts, 0 watch items out of 17 risk checks; no TTM dividend.
Close PriceHK$4.43Day +5.48%Market CapHK$23.59BP/E—Negative earningsP/B74.94xROE (FY2025)-41.1%Avg. equity

Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for JINHAI MED TECH?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2016–2025

Key Multi-Year Facts

  • Revenue moved from HK$45.1M in FY2016 to HK$46.3M in FY2025 (9-year CAGR +0.3%).
  • Net income was negative in FY2018, FY2019, FY2021, FY2023, FY2024, FY2025.
  • Operating cash flow was below half of net income in FY2017.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (HKD B)0.020.020.050.050.05
YoY-2.6%1.8%104.9%10.1%-7.9%
Net Income (HKD B)-0.000.00-0.00-0.02-0.02
YoY-119.5%—-771.2%——
Operating Cash Flow (HKD B)0.020.02-0.01-0.02-0.03
ROE-1.0%1.9%-10.2%-51.9%-41.1%
Gross Margin35.3%45.4%26.4%22.8%15.5%
Net Margin-1.1%2.1%-6.9%-35.8%-36.9%
Debt-to-Assets28.9%38.9%39.7%44.3%41.5%
Show all 10 fiscal years
Fiscal Year2016201720182019202020212022202320242025
Revenue (HKD B)0.050.040.050.050.020.020.020.050.050.05
YoY—-1.4%6.8%9.4%-56.7%-2.6%1.8%104.9%10.1%-7.9%
Net Income (HKD B)0.010.00-0.00-0.000.00-0.000.00-0.00-0.02-0.02
YoY—-65.6%-255.4%——-119.5%—-771.2%——
Operating Cash Flow (HKD B)0.04-0.01-0.010.040.040.020.02-0.01-0.02-0.03
ROE66.4%11.6%-13.0%-2.8%5.1%-1.0%1.9%-10.2%-51.9%-41.1%
Gross Margin34.4%26.4%18.7%23.9%39.4%35.3%45.4%26.4%22.8%15.5%
Net Margin14.7%5.1%-7.5%-1.3%5.6%-1.1%2.1%-6.9%-35.8%-36.9%
Debt-to-Assets62.4%23.0%26.4%43.2%35.3%28.9%38.9%39.7%44.3%41.5%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-05

Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).

3Alert 0Watch 13Pass 1N/A

Items Flagged for Review

  • Alert

    Receivables DaysFinancial Quality

    121.3 days, prior FY 35.3 days(+244%)

    FY2025 (ended 2025-12-31) · What is this?

  • Alert

    Interest CoverageSolvency

    Negative (negative EBIT)

    FY2025 (ended 2025-12-31) · What is this?

  • Alert

    Net LossesGoing Concern

    FY2025 (2025-12-31) HK$-0.02B, FY2024 (2024-12-31) HK$-0.02B

    FY2025 (ended 2025-12-31)

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

Dividends

No dividends paid over the trailing 12 months.

Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.

More data: All research reports · Sector leaders · Market hours & holidays.

Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.